Spyre Therapeutics (SYRE) highlighted its 2026 priorities including six expected POC readouts. The Company also expanded its leadership team with the appointment of Kate Tansey Chevlen as Chief Commercial Officer, CCO. Tansey Chevlen is a biopharma commercial leader with nearly two decades of experience, joining from Ampgen where she most recently held the position of VP, Global Marketing Head for Immunology and Inflammation. Key highlights: SKYLINE platform trial in ulcerative colitis recruiting faster than expected with SPY001 enrollment complete ahead of schedule; Part A readouts accelerated, now expected to start in Q2; SKYWAY basket trial enrollment on track across rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis; All readouts expected in 4Q 2026; Strong balance sheet with pro forma cash, cash equivalents, and marketable securities balance of $783M as of September 30, 2025, anticipated to provide cash runway into the second half of 2028
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics: TL1A Blockade Opportunity in Rheumatology Underpins Buy Rating and $64 Target
- Spyre Therapeutics falls -7.4%
- Spyre Therapeutics: TL1A-Driven Inflammatory Arthritis Opportunity Underpins Buy Rating and $64 Target
- Spyre Therapeutics initiated with an Outperform at Mizuho
- Spyre Therapeutics initiated with a Buy at Citi